NT-proBNP During Screening in the Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial: Insights Into Outcomes and Vericiguat
Host: Cynthia M. Westerhout, PhD
\n\n\n \n
In this program, expert faculty discuss data presented at the 2023 ACC Congress in a concise, informative, on-demand format. This format extends the congress analysis to a broader audience with greater detail than what is available in abstracts. Rapid advances from the meeting require well-planned educational programming to bridge knowledge, competence, and performance gaps.